Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Rentschler Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Rentschler Biopharma’s ATMP site will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel AAV-based therapy for the treatment of geographic atrophy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Rentschler Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : UKi2S
Deal Size : $3.2 million
Deal Type : Funding
Ophthalmic gene therapy company launches with £2.5m seed cash
Details : The cash will primarily take the company’s lead programme, a multicistronic gene therapy for diabetic macular edema (DME), to IND-enabling studies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 05, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : UKi2S
Deal Size : $3.2 million
Deal Type : Funding
Reset All
